Abstract
β-d-glucan (Fungitell) and polymerase chain reaction-based (T2Candida) assays of blood samples are FDA-approved adjuncts to cultures for diagnosing candidemia and other types of invasive candidiasis, but their clinical roles are unclear. In this chapter, we describe laboratory protocols for performing Fungitell and T2Candida assays. We then discuss step-by-step methods for interpreting test results at the bedside using a Bayesian framework, and for incorporating assays into rational patient management strategies. Prior to interpreting results, clinicians must recognize that test performance varies based on the type of invasive candidiasis being diagnosed. In general, the type of invasive candidiasis that is most likely in a given patient can be identified, and the pretest likelihood of disease estimated. From there, positive and negative predictive values (PPV, NPV) for an assay can be calculated. At a population level, tests can be incorporated into screening strategies for antifungal treatment. NPV and PPV thresholds can be defined for discontinuing antifungal prophylaxis or initiating preemptive treatment, respectively. Using the thresholds, it is possible to assign windows of pretest likelihood for invasive candidiasis (and corresponding patient populations) in which tests are most likely to valuable. At the individual patient level, tests may be useful outside of the windows proposed for screening populations. The interpretive and clinical decision-making processes we discuss will be applicable to other diagnostic assays as they enter the clinic, and to existing assays as more data emerge from various populations.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Clancy CJ, Nguyen MH (2013) Finding the “missing 50%” of invasive candidiasis: how nonculture diagnostics will improve understanding of disease spectrum and transform patient care. Clin Infect Dis 56(9):1284–1292. doi:10.1093/cid/cit006
Andes DR, Safdar N, Baddley JW, Playford G, Reboli AC, Rex JH, Sobel JD, Pappas PG, Kullberg BJ (2012) Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials. Clin Infect Dis 54(8):1110–1122. doi:10.1093/cid/cis021
Wheat LJ (2009) Approach to the diagnosis of invasive aspergillosis and candidiasis. Clin Chest Med 30(2):367–377, viii. doi:10.1016/j.ccm.2009.02.012
Nguyen MH, Wissel MC, Shields RK, Salomoni MA, Hao B, Press EG, Shields RM, Cheng S, Mitsani D, Vadnerkar A, Silveira FP, Kleiboeker SB, Clancy CJ (2012) Performance of Candida real-time polymerase chain reaction, beta-D-glucan assay, and blood cultures in the diagnosis of invasive candidiasis. Clin Infect Dis 54(9):1240–1248. doi:10.1093/cid/cis200
Tissot F, Lamoth F, Hauser PM, Orasch C, Fluckiger U, Siegemund M, Zimmerli S, Calandra T, Bille J, Eggimann P, Marchetti O (2013) Beta-glucan antigenemia anticipates diagnosis of blood culture-negative intraabdominal candidiasis. Am J Respir Crit Care Med 188(9):1100–1109. doi:10.1164/rccm.201211-2069OC
Calandra T, Bille J, Schneider R, Mosimann F, Francioli P (1989) Clinical significance of Candida isolated from peritoneum in surgical patients. Lancet 2(8677):1437–1440, S0140-6736(89)92043-6 [pii]
Leroy O, Gangneux JP, Montravers P, Mira JP, Gouin F, Sollet JP, Carlet J, Reynes J, Rosenheim M, Regnier B, Lortholary O (2009) Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: a multicenter, prospective, observational study in France (2005–2006). Crit Care Med 37(5):1612–1618. doi:10.1097/CCM.0b013e31819efac0
Karageorgopoulos DE, Vouloumanou EK, Ntziora F, Michalopoulos A, Rafailidis PI, Falagas ME (2011) Beta-D-glucan assay for the diagnosis of invasive fungal infections: a meta-analysis. Clin Infect Dis 52(6):750–770. doi:10.1093/cid/ciq206
He S, Hang JP, Zhang L, Wang F, Zhang DC, Gong FH (2014) A systematic review and meta-analysis of diagnostic accuracy of serum 1,3-beta-d-glucan for invasive fungal infection: focus on cutoff levels. J Microbiol Immunol Infect. doi:10.1016/j.jmii.2014.06.009
Mylonakis E, Clancy CJ, Ostrosky-Zeichner L, Garey KW, Alangaden GJ, Vazquez JA, Groeger SJ, Judson MA, Vinagre YM, Heard SO, Zervou FN, Zacharioudakis IM, Kontoyiannis DP, Pappas PG (2015) T2 magnetic resonance assay for the rapid diagnosis of candidemia in whole blood: a clinical trial. Clin Infect Dis 60:892–899
Neely LA, Audeh M, Phung NA, Min M, Suchocki A, Plourde D, Blanco M, Demas V, Skewis LR, Anagnostou T, Coleman JJ, Wellman P, Mylonakis E, Lowery TJ (2013) Magnetic resonance enables nanoparticle-mediated rapid detection of candidemia in whole blood. Sci Transl Med 5(182):182ra154. doi:10.1126/scitranslmed.3005377
Avni T, Leibovici L, Paul M (2011) PCR diagnosis of invasive candidiasis: systematic review and meta-analysis. J Clin Microbiol 49(2):665–670. doi:10.1128/JCM.01602-10
Delaloye J, Calandra T (2014) Invasive candidiasis as a cause of sepsis in the critically ill patient. Virulence 5(1):161–169. doi:10.4161/viru.26187
Michalopoulos AS, Geroulanos S, Mentzelopoulos SD (2003) Determinants of candidemia and candidemia-related death in cardiothoracic ICU patients. Chest 124(6):2244–2255
Kett DH, Azoulay E, Echeverria PM, Vincent JL (2011) Candida bloodstream infections in intensive care units: analysis of the extended prevalence of infection in intensive care unit study. Crit Care Med 39(4):665–670. doi:10.1097/CCM.0b013e318206c1ca
Ostrosky-Zeichner L, Sable C, Sobel J, Alexander BD, Donowitz G, Kan V, Kauffman CA, Kett D, Larsen RA, Morrison V, Nucci M, Pappas PG, Bradley ME, Major S, Zimmer L, Wallace D, Dismukes WE, Rex JH (2007) Multicenter retrospective development and validation of a clinical prediction rule for nosocomial invasive candidiasis in the intensive care setting. Eur J Clin Microbiol Infect Dis 26(4):271–276. doi:10.1007/s10096-007-0270-z
Hadley S, Lee WW, Ruthazer R, Nasraway SA Jr (2002) Candidemia as a cause of septic shock and multiple organ failure in nonimmunocompromised patients. Crit Care Med 30(8):1808–1814
Ostrosky-Zeichner L, Shoham S, Vazquez J, Reboli A, Betts R, Barron MA, Schuster M, Judson MA, Revankar SG, Caeiro JP, Mangino JE, Mushatt D, Bedimo R, Freifeld A, Nguyen MH, Kauffman CA, Dismukes WE, Westfall AO, Deerman JB, Wood C, Sobel JD, Pappas PG (2014) MSG-01: a randomized, double-blind, placebo-controlled trial of caspofungin prophylaxis followed by preemptive therapy for invasive candidiasis in high-risk adults in the critical care setting. Clin Infect Dis 58:1219–1226. doi:10.1093/cid/ciu074
Paphitou NI, Ostrosky-Zeichner L, Rex JH (2005) Rules for identifying patients at increased risk for candidal infections in the surgical intensive care unit: approach to develo** practical criteria for systematic use in antifungal prophylaxis trials. Med Mycol 43(3):235–243
Eschenauer GA, Kwak EJ, Humar A, Potoski BA, Clarke LG, Shields RK, Abdel-Massih R, Silveira FP, Vergidis P, Clancy CJ, Nguyen MH (2015) Targeted versus universal antifungal prophylaxis among liver transplant recipients. Am J Transplant 15:180–189. doi:10.1111/ajt.12993
Matuszkiewicz-Rowinska J (2009) Update on fungal peritonitis and its treatment. Perit Dial Int 29(Suppl 2):S161–S165
Hall AM, Poole LA, Renton B, Wozniak A, Fisher M, Neal T, Halloran CM, Cox T, Hampshire PA (2013) Prediction of invasive candidal infection in critically ill patients with severe acute pancreatitis. Crit Care 17(2):R49. doi:10.1186/cc12569
Gill CJ, Sabin L, Schmid CH (2005) Why clinicians are natural bayesians. BMJ 330(7499):1080–1083. doi:10.1136/bmj.330.7499.1080
Pfeiffer CD, Samsa GP, Schell WA, Reller LB, Perfect JR, Alexander BD (2011) Quantitation of Candida CFU in initial positive blood cultures. J Clin Microbiol 49(8):2879–2883. doi:10.1128/JCM.00609-11
Telenti A, Steckelberg JM, Stockman L, Edson RS, Roberts GD (1991) Quantitative blood cultures in candidemia. Mayo Clin Proc 66(11):1120–1123
Playford EG, Webster AC, Sorrell TC, Craig JC (2006) Antifungal agents for preventing fungal infections in non-neutropenic critically ill and surgical patients: systematic review and meta-analysis of randomized clinical trials. J Antimicrob Chemother 57(4):628–638. doi:10.1093/jac/dki491
Shorr AF, Chung K, Jackson WL, Waterman PE, Kollef MH (2005) Fluconazole prophylaxis in critically ill surgical patients: a meta-analysis. Crit Care Med 33(9):1928–1935, quiz 1936
Eggimann P, Francioli P, Bille J, Schneider R, Wu MM, Chapuis G, Chiolero R, Pannatier A, Schilling J, Geroulanos S, Glauser MP, Calandra T (1999) Fluconazole prophylaxis prevents intra-abdominal candidiasis in high-risk surgical patients. Crit Care Med 27(6):1066–1072
Garbino J, Lew DP, Romand JA, Hugonnet S, Auckenthaler R, Pittet D (2002) Prevention of severe Candida infections in nonneutropenic, high-risk, critically ill patients: a randomized, double-blind, placebo-controlled trial in patients treated by selective digestive decontamination. Intensive Care Med 28(12):1708–1717. doi:10.1007/s00134-002-1540-y
Pelz RK, Hendrix CW, Swoboda SM, Diener-West M, Merz WG, Hammond J, Lipsett PA (2001) Double-blind placebo-controlled trial of fluconazole to prevent candidal infections in critically ill surgical patients. Ann Surg 233(4):542–548
Goodman JL, Winston DJ, Greenfield RA, Chandrasekar PH, Fox B, Kaizer H, Shadduck RK, Shea TC, Stiff P, Friedman DJ et al (1992) A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 326(13):845–851. doi:10.1056/NEJM199203263261301
Slavin MA, Osborne B, Adams R, Levenstein MJ, Schoch HG, Feldman AR, Meyers JD, Bowden RA (1995) Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation—a prospective, randomized, double-blind study. J Infect Dis 171(6):1545–1552
Muldoon EG, Denning DW (2014) Editorial commentary: Prophylactic echinocandin: is there a subgroup of intensive care unit patients who benefit? Clin Infect Dis 58(9):1227–1229. doi:10.1093/cid/ciu080
Akamatsu N, Sugawara Y, Kaneko J, Tamura S, Makuuchi M (2007) Preemptive treatment of fungal infection based on plasma (1 → 3)beta-D-glucan levels after liver transplantation. Infection 35(5):346–351. doi:10.1007/s15010-007-6240-7
Jaijakul S, Vazquez JA, Swanson RN, Ostrosky-Zeichner L (2012) (1,3)-Bta-D-glucan as a prognostic marker of treatment response in invasive candidiasis. Clin Infect Dis 55(4):521–526. doi:10.1093/cid/cis456
Financial Disclosures/Acknowledgements
Drs. Clancy and Nguyen have served as site PIs for diagnostic clinical trials funded by T2 Biosystems. Dr. Clancy has received financial support for investigator-initiated research projects from Pfizer, Merck, and CSL Behring. Dr. Nguyen has received financial support for investigator-initiated research projects from Pfizer, Merck, Astellas, and Vira-Cor IBT. The authors received no funding or other assistance for the preparation of this manuscript.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer Science+Business Media New York
About this protocol
Cite this protocol
Clancy, C.J., Nguyen, M.H. (2016). Diagnostic Methods for Detection of Blood-Borne Candidiasis. In: Calderone, R., Cihlar, R. (eds) Candida Species. Methods in Molecular Biology, vol 1356. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-3052-4_16
Download citation
DOI: https://doi.org/10.1007/978-1-4939-3052-4_16
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-3051-7
Online ISBN: 978-1-4939-3052-4
eBook Packages: Springer Protocols